Search for: "Lilly v. Heard"
Results 81 - 100
of 140
Sorted by Relevance
|
Sort by Date
7 Dec 2014, 3:29 pm
Among the significant –- but, really, very-well indexed –- number of issues, the decision delves into novelty, inventive step, insufficiency by excessive claim breadth, added matter, and claim construction in light of the influential Actavis v Eli Lilly, another Arnoldian decision that the very same judge clarifies further in this ruling. [read post]
10 Nov 2010, 1:11 am
Becton-Dickinson (Patent Docs) US government intervenes in patentability of genes – AMP v USPTO (Patent Baristas) (Holman’s Biotech IP Blog) (Intellectual Property Law Blog) (Inovia) (BlawgIT) (IP Osgoode) US: BIO and AUTM fire back at gene patent foes – AMP v USPTO (Patent Baristas) (Patent Docs) US: IPO files amicus brief in AMP v USPTO (Patent Docs) (Patent Baristas) US: AIPLA submits amicus brief in AMP v USPTO (Patent Docs) US: Summary of… [read post]
26 Feb 2013, 4:03 pm
Eady J heard the first cases on Offer of Amends under s2-4 of the Defamation Act 1996. [read post]
21 Sep 2020, 12:00 am
In Sisvel v. [read post]
17 Jan 2019, 11:09 pm
In many circumstances, she had to make a decision because the law required it but it was not necessarily the best thing for the family.Inevitably there was some discussion about the implications of Actavis v Eli Lilly [2017] UKSC 48. [read post]
6 Jul 2010, 6:03 pm
Siemens (EPLAW) India: Novartis & Bayer appeals to be heard by the Supreme Court in the next 30 days (Spicy IP) US: House passes patent settlement legislation as part of the War Funding Bill (FDA Law Blog) US: Bilski v Kappos: What effects on biotechnology patents? [read post]
7 Jul 2010, 5:14 am
Siemens (EPLAW) India: Novartis & Bayer appeals to be heard by the Supreme Court in the next 30 days (Spicy IP) US: House passes patent settlement legislation as part of the War Funding Bill (FDA Law Blog) US: Bilski v Kappos: What effects on biotechnology patents? [read post]
1 Oct 2020, 8:00 am
Connick v. [read post]
3 Jun 2010, 1:37 pm
Eli Lilly & Co., 854 N.E.2d 372 (Ind. [read post]
25 May 2015, 1:28 am
In Human Genome Sciences Inc. v Eli Lilly and Company [2011] UKSC 51 the Supreme Court reversed the findings of the High Court and Court of Appeal. [read post]
18 Nov 2011, 6:51 am
The IPKat heard about this from a number of sources which included, via the social media, the IPO itself. [read post]
11 Aug 2010, 1:15 am
and industrial applicability in Eli Lilly & Co v Human Genome Sciences Inc, noted by the IPKat here, is (according to a normally reliable source whom the Kat thanks) to be heard by the Supreme Court on Thursday 7 October. [read post]
21 Jun 2024, 4:04 pm
(I've heard that Justice Ginsburg had a signed copy of that bill on her chamber walls.) [read post]
15 Nov 2013, 11:34 am
Eli Lilly & Co. v. [read post]
13 Apr 2019, 12:25 pm
| Applying the Actavis questions to numerical limitations: Regen Lab v Estar | Formstein defence in the UK? [read post]
Discovery Rule, Cross-Jurisdictional Tolling, and "Equitable" Tolling Cannot Save Aredia-Zometa Case
16 Oct 2013, 4:30 am
In Jolly v. [read post]
28 Jun 2013, 5:02 am
The court in Saavedra v. [read post]
10 Jun 2014, 7:44 pm
In this post, guest contributor Paul England (Taylor Wessing LLP) explains the legal issues and their consequences:UKIPO -- a 'court' for the purposes of the Brussels I Regulation Some courts look like this ...With Actavis v Eli Lilly [noted on the IPKat here] still fresh in our minds, and amendments to the Brussels I Regulation (recast) progressing through the European Parliament in preparation for the Unified Patent Court, jurisdictional matters are a hot… [read post]
29 Nov 2006, 11:41 am
On Monday, the Supreme Court heard argument in Ledbetter v. [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) - US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP Watch) Is the practice of medicine… [read post]
